Advertisement
Canada markets open in 2 hours 2 minutes

  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CAD/USD

    0.7295
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    81.60
    +0.03 (+0.04%)
     

  • Bitcoin CAD

    90,982.46
    +1,371.80 (+1.53%)
     

  • CMC Crypto 200

    1,379.07
    -3.59 (-0.26%)
     

  • GOLD FUTURES

    2,353.00
    +6.10 (+0.26%)
     

  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     

  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     

  • NASDAQ futures

    20,040.25
    +121.00 (+0.61%)
     

  • VOLATILITY

    12.59
    +0.11 (+0.88%)
     

  • FTSE

    8,238.70
    +33.59 (+0.41%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • CAD/EUR

    0.6797
    +0.0010 (+0.15%)
     

Amneal to Participate at Upcoming Investor Conference

Business Wire
·1 min read

BRIDGEWATER, N.J., May 22, 2024--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024.

Chirag will present at 1:30 PM EST. A live webcast of the presentation will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available following the event.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 generic and specialty pharmaceuticals, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522763089/en/

Contacts

Investor Contact:
Anthony DiMeo
VP, Investor Relations & Media
anthony.dimeo@amneal.com